Aktuellt
SENASTE
Following the successful acquisition of Cyano Biotech GmbH in Q3, Simris is now moving forward with a three-pronged approach to value creation. First in line is the relaunch of food supplements in the US and Sweden starting in Q4’22. Second, over the winter, Simris will conduct further trials to optimize production of Fucoxanthin and advance its B2B offering, which we expect to produce results by summer 2023. Finally, for Simris’ entry into the high-value biopharma space, we see a good chance for a first evaluation agreement based on Cyano’ platform for ADC payloads within our forecast horizon. All in all, we continue to find support for a fair value of SEK 170-230m in 12-24 months.
LÄS MER
